NovaSperse℠ is a novel cost-effective process used to create amorphous spherical nanoparticle formulations of pure, poorly soluble APIs to enhance solubility, improve bioavailability and enable all delivery routes.

NovaSperse℠ is a proprietary platform technology used to create amorphous nanoparticles of poorly water-soluble drugs. Spherical nanoparticles of pure drug substances can be created providing enhanced solubility and with numerous other advantages over nano-crystals and other particle types.  PharmaNova's NovaSperse℠ process uses GRAS surfactants and polymers to stabilize the nanoparticles and is scalable.

NovaSperse℠, based on solvent displacement principles, allows i) control over the formation of nuclei and molecular aggregates, ii) production of tailor-made particle sizes, and iii) narrow particle size distribution around the mean.   PharmaNova has a library of nanoparticulate APIs that range in molecular weight from 200 to 1200 and differ widely in molecular complexity and physico-chemical properties. PharmaNova's NovaSperse℠ products are in development as proprietary formulations suitable for various routes of administration e.g. ocular, topical, oral and parenteral.

Preclinical

Pending

PharmaNova is seeking licensees and/or partners, with whom to collaborate on the development of NPOs, and clients to enhance the properties of their proprietary APIs, through application of our NovaSperse℠ nanoparticle technology on a fee-for-service basis.

Pending